HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment

Retrovirology

Volumn 7, Issue , 2010, Pages

  Hauser, Heiko ^a   Lopez, Lisa A ^a   Yang, Su J ^a   Oldenburg, Jill E ^a   Exline, Colin M ^a   Guatelli, John C ^b,c   Cannon, Paula M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BST 2 PROTEIN; MEMBRANE PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VPU PROTEIN; BST2 PROTEIN, HUMAN; GLYCOPROTEIN GP 160; GP160 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LEUKOCYTE ANTIGEN; VIRUS PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; CELL LEVEL; CELL SURFACE; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; TRANS GOLGI NETWORK; VIRUS PARTICLE; CELL LINE; CELL MEMBRANE; CHEMISTRY; CONFOCAL MICROSCOPY; ENDOPLASMIC RETICULUM; FLUORESCENCE MICROSCOPY; HOST PATHOGEN INTERACTION; METABOLISM; PATHOGENICITY; PROTEIN ANALYSIS; PROTEIN BINDING;

HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; SIMIAN IMMUNODEFICIENCY VIRUS;

ANTIGENS, CD; CELL LINE; CELL MEMBRANE; ENDOPLASMIC RETICULUM; HIV ENVELOPE PROTEIN GP160; HIV-1; HIV-2; HOST-PATHOGEN INTERACTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EID: 77953044868     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-51     Document Type: Article

References (48)

1. Anderson JL, Hope TJ. HIV accessory proteins and surviving the host cell. Curr HIV/AIDS Rep 2004, 1:47-53. 10.1007/s11904-004-0007-x, 16091223.
2. Neil SJ, Sandrin V, Sundquist WI, Bieniasz PD. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007, 2:193-203. 10.1016/j.chom.2007.08.001, 18005734.
3. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430. 10.1038/nature06553, 18200009.
4. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, Stephens EB, Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3:245-252. 10.1016/j.chom.2008.03.001, 2474773, 18342597.
5. Klimkait T, Strebel K, Hoggan MD, Martin MA, Orenstein JM. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J Virol 64:621-629. 249152, 2404139.
6. Nomaguchi M, Fujita M, Adachi A. Role of HIV-1 Vpu protein for virus spread and pathogenesis. Microbes Infect 2008, 10:960-967. 10.1016/j.micinf.2008.07.006, 18672082.
7. Abada P, Noble B, Cannon PM. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J Virol 2005, 79:3627-3638. 10.1128/JVI.79.6.3627-3638.2005, 1075700, 15731257.
8. Gottlinger HG, Dorfman T, Cohen EA, Haseltine WA. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci USA 1993, 90:7381-7385. 10.1073/pnas.90.15.7381, 47141, 8346259.
9. Jouvenet N, Neil SJ, Zhadina M, Zang T, Kratovac Z, Lee Y, McNatt M, Hatziioannou T, Bieniasz PD. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 2009, 83:1837-1844. 10.1128/JVI.02211-08, 2643743, 19036818.
10. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. Inhibition of Lassa and Marburg virus production by tetherin. J Virol 2009, 83:2382-2385. 10.1128/JVI.01607-08, 2643706, 19091864.
11. Bour S, Strebel K. The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J Virol 1996, 70:8285-8300. 190916, 8970948.
12. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci USA 2009, 106:2886-91. 10.1073/pnas.0811014106, 2650360, 19179289.
13. Le Tortorec A, Neil SJ. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J Virol 2009, 83:11966-11978. 10.1128/JVI.01515-09, 2772693, 19740980.
14. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog 2009, 5:e1000429. 10.1371/journal.ppat.1000429, 2673686, 19436700.
15. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, Hatziioannou T. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009, 6:54-67. 10.1016/j.chom.2009.05.008, 2852097, 19501037.
16. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 2010, 7:13. 10.1186/1742-4690-7-13, 2831821, 20167081.
17. Sauter D, Schindler M, Specht A, Landford WN, Münch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, Takehisa J, Ogando Y, Ochsenbauer C, Kappes JC, Ayouba A, Peeters M, Learn GH, Shaw G, Sharp PM, Bieniasz P, Hahn BH, Hatziioannou T, Kirchhoff F. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6:409-421. 10.1016/j.chom.2009.10.004, 19917496.
18. Bartee E, McCormack A, Fruh K. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2006, 2:e107. 10.1371/journal.ppat.0020107, 1626102, 17238276.
19. Mansouri M, Viswanathan K, Douglas JL, Hines J, Gustin J, Moses AV, Fruh K. Molecular mechanism of BST2/Tetherin downregulation by K5/MIR2 of Kaposi's sarcoma herpesvirus. J Virol 2009, 83:9672-9681. 10.1128/JVI.00597-09, 2748026, 19605472.
20. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003, 4:694-709. 10.1034/j.1600-0854.2003.00129.x, 12956872.
21. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 2007, 120:3850-3858. 10.1242/jcs.003343, 17940069.
22. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, Bieniasz PD. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139:499-511. 10.1016/j.cell.2009.08.039, 2844890, 19879838.
23. Miyagi E, Andrew AJ, Kao S, Strebel K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci USA 2009, 106:2868-73. 10.1073/pnas.0813223106, 2650357, 19196977.
24. Goffinet C, Allespach I, Homann S, Tervo HM, Habermann A, Rupp D, Oberbremer L, Kern C, Tibroni N, Welsch S, Krijnse-Locker J, Banting G, Krausslich HG, Fackler OT, Keppler OT. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009, 5:285-297. 10.1016/j.chom.2009.01.009, 19286137.
25. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, Moses AV. Vpu Directs the Degradation of the HIV Restriction Factor BST-2/tetherin via a {beta}TrCP-dependent Mechanism. J Virol 2009, 83:7931-7947. 10.1128/JVI.00242-09, 2715753, 19515779.
26. Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y, Sata T, Tokunaga K. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J Biol Chem 2009, 284:35060-35072. 10.1074/jbc.M109.058305, 19837671.
27. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, Stephens EB, Margottin-Goguet F, Benarous R, Guatelli JC. Vpu Antagonizes BST-2-Mediated Restriction of HIV-1 Release via beta-TrCP and Endo-Lysosomal Trafficking. PLoS Pathog 2009, 5:e1000450. 10.1371/journal.ppat.1000450, 2679223, 19478868.
28. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 2006, 177:3260-3265.
29. Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, Leung G, Cohen EA. Suppression of Tetherin-Restricting Activity on HIV-1 Particle Release Correlates with Localization of Vpu in the trans-Golgi Network. J Virol 2009, 83:4574-4590. 10.1128/JVI.01800-08, 2668474, 19244337.
30. Masuyama N, Kuronita T, Tanaka R, Muto T, Hirota Y, Takigawa A, Fujita H, Aso Y, Amano J, Tanaka Y. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin. J Biol Chem 2009, 284:15927-15941. 10.1074/jbc.M109.005124, 2708888, 19359243.
31. Bieniasz PD. Intrinsic immunity: a front-line defense against viral attack. Nat Immunol 2004, 5:1109-1115. 10.1038/ni1125, 15496950.
32. Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, Thomas D, Strebel K, Benarous R. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell 1998, 1:565-574. 10.1016/S1097-2765(00)80056-8, 9660940.
33. Kasper MR, Collins KL. Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells. J Virol 2003, 77:3041-3049. 10.1128/JVI.77.5.3041-3049.2003, 149742, 12584329.
34. Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL. HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. PLoS Pathog 2008, 4:e1000131. 10.1371/journal.ppat.1000131, 2515349, 18725938.
35. Nathan JA, Lehner PJ. The trafficking and regulation of membrane receptors by the RING-CH ubiquitin E3 ligases. Exp Cell Res 2009, 315:1593-1600. 10.1016/j.yexcr.2008.10.026, 19013150.
36. Gupta RK, Hue S, Schaller T, Verschoor E, Pillay D, Towers GJ. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog 2009, 5:e1000443. 10.1371/journal.ppat.1000443, 2678251, 19461879.
37. Goffinet C, Homann S, Ambiel I, Tibroni N, Rupp D, Keppler OT, Fackler OT. Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J Virol 2010, 84:4089-4094. 10.1128/JVI.01549-09, 20147395.
38. Estrabaud E, Le Rouzic E, Lopez-Verges S, Morel M, Belaidouni N, Benarous R, Transy C, Berlioz-Torrent C, Margottin-Goguet F. Regulated degradation of the HIV-1 Vpu protein through a betaTrCP-independent pathway limits the release of viral particles. PLoS Pathog 2007, 3:e104. 10.1371/journal.ppat.0030104, 1933454, 17676996.
39. Friborg J, Ladha A, Gottlinger H, Haseltine WA, Cohen EA. Functional analysis of the phosphorylation sites on the human immunodeficiency virus type 1 Vpu protein. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:10-22.
40. Rong L, Zhan J, Pan JLQ, Lorgeoux RP, Aloysius C, Guo F, Liu SL, Wainberg MA, Liang C. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol 2009, 83:7536-7546. 10.1128/JVI.00620-09, 2708638, 19474106.
41. Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 1992, 66:7193-7200. 240416, 1433512.
42. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its betaTrCP2-dependent degradation. PLoS Pathog 2009, 5:e1000574. 10.1371/journal.ppat.1000574, 2729927, 19730691.
43. Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, Takeuchi Y, Marsh M, Towers GJ. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc Natl Acad Sci USA 2009,
44. Noble B, Abada P, Nunez-Iglesias J, Cannon PM. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J Virol 2006, 80:2924-2932. 10.1128/JVI.80.6.2924-2932.2006, 1395462, 16501101.
45. Bour S, Akari H, Miyagi E, Strebel K. Naturally occurring amino acid substitutions in the HIV-2 ROD envelope glycoprotein regulate its ability to augment viral particle release. Virology 2003, 309:85-98. 10.1016/S0042-6822(02)00128-9, 12726729.
46. Lopez LA, Yang SJ, Hauser H, Exline CM, Haworth KG, Oldenburg J, Cannon PM. Ebola glycoprotein counteracts BST-2/tetherin restriction in a sequence independent manner that does not require tetherin surface removal. J Virol 2010,
47. Nguyen KL, llano M, Akari H, Miyagi E, Poeschla EM, Strebel K, Bour S. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 2004, 319:163-175. 10.1016/j.virol.2003.11.021, 15015498.
48. Varthakavi VR, Smith M, Martin KL, Derdowski A, Lapierre LA, Goldenring JR, Spearman P. The pericentriolar recycling endosome plays a key role in Vpu-mediated enhancement of HIV-1 particle release. Traffic 2006, 7:298-307. 10.1111/j.1600-0854.2005.00380.x, 16497224.